Handelsbanken Fonder AB Has $1.84 Million Stock Holdings in Chemed Corporation $CHE

Handelsbanken Fonder AB reduced its holdings in shares of Chemed Corporation (NYSE:CHE) by 5.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,772 shares of the company’s stock after selling 200 shares during the period. Handelsbanken Fonder AB’s holdings in Chemed were worth $1,837,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Creekmur Asset Management LLC acquired a new stake in Chemed during the second quarter valued at approximately $28,000. SVB Wealth LLC bought a new position in shares of Chemed during the 1st quarter worth approximately $30,000. WPG Advisers LLC acquired a new stake in Chemed in the 1st quarter valued at $32,000. Parkside Financial Bank & Trust grew its position in Chemed by 86.3% in the second quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after acquiring an additional 44 shares during the period. Finally, Geneos Wealth Management Inc. raised its stake in Chemed by 330.4% during the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Insider Buying and Selling at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 3,000 shares of the company’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the transaction, the chief executive officer directly owned 96,197 shares in the company, valued at approximately $44,373,752.16. This represents a 3.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Patrick P. Grace sold 150 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares in the company, valued at $1,574,135.83. This trade represents a 4.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,150 shares of company stock worth $2,328,449 in the last ninety days. 3.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CHE shares. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, October 8th. Bank of America decreased their price objective on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. Oppenheimer dropped their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada dropped their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Chemed currently has an average rating of “Moderate Buy” and a consensus target price of $574.25.

Chemed Trading Up 0.1%

Shares of CHE stock opened at $441.09 on Thursday. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60. The firm’s 50 day moving average is $441.15 and its 200-day moving average is $475.74. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of 23.33, a PEG ratio of 2.69 and a beta of 0.43.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The company had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. During the same period in the prior year, the business earned $5.64 EPS. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities research analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Monday, November 17th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, November 17th. Chemed’s dividend payout ratio is 12.69%.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.